NCT05116189 2026-03-09KEYNOTE-B96Merck Sharp & Dohme LLCPhase 3 Active not recruiting643 enrolled 17 charts 1 FDA
NCT02253316 2025-11-10Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaWashington University School of MedicinePhase 2 Active not recruiting236 enrolled 13 charts
NCT03740165 2025-10-22KEYLYNK-001Merck Sharp & Dohme LLCPhase 3 Active not recruiting1,367 enrolled 29 charts